AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27583276
Drug: CoQ10 (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (2,400 mg/d)
Trial: 27583590
Drug: Atazanavir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 400 mg once-daily
Trial: 27583590
Drug: Higher unboosted
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher unboosted doses or splitting the daily dose to twice-daily
Trial: 27583892
Drug: NOACs (non-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs (non-vitamin K antagonist oral anticoagulants) - appropriate treatment (AT)
Trial: 27583892
Drug: NOACs (non-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs (non-vitamin K antagonist oral anticoagulants) - undertreatment (UT)
Trial: 27583892
Drug: NOACs (non-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs (non-vitamin K antagonist oral anticoagulants) - overtreatment (OT)
Trial: 27586891
Drug: Buspirone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 20 mg daily for 4 weeks
Trial: 27587380
Drug: First salvage
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First salvage treatment
Trial: 27587380
Drug: Second salvage
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second salvage treatment
Trial: 27587380
Drug: Third or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third or greater salvage treatment
Trial: 27588424
Drug: Drisapersen, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drisapersen, 6 mg/kg subcutaneously, once weekly for 72 weeks, followed by intermittent dosing for 108 weeks (total 188 weeks)
Trial: 27589870
Drug: Patient related
RxNorm normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient related quality of life (measured using EQ-5D-5 L)
Trial: 27590145
Drug: CC-930 (JNK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-930 (JNK inhibitor)
Trial: 27595276
Drug: TAPS tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAPS tool (interviewer-administered)
Trial: 27595276
Drug: TAPS tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAPS tool (self-administered)
Trial: 27595685
Drug: Monthly benchmarked
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly benchmarked hospital quality reports and recognition of hospital quality achievement.
Trial: 27597733
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg intravenous bolus, dosing determined by up-and-down method)
Trial: 27597740
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept administered at baseline and at 1, 2, and 4 months
Trial: 27599452
Drug: Tablet-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based training to engage with Personal Health Record (PHR)
Trial: 27600044
Drug: Voriconazole administration
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole administration
Trial: 27601554
Drug: AZD1775 as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 as monotherapy (single dose)
Trial: 27601554
Drug: AZD1775 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 in combination with gemcitabine (1,000 mg/m2)
Trial: 27601554
Drug: AZD1775 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 in combination with cisplatin or carboplatin
Trial: 27602311
Drug: Mesenchymal stromal
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cells (20 million cells implanted once into the nonunion site using a fluoroscopic guide) in combination with platelet lysate (PL) product
Trial: 27602967
Drug: 20 mg/ml
RxNorm normalized name: urea 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/ml hyaluronic acid filler (Juvéderm Voluma® XC)
Trial: 27603290
Drug: Streamlined delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streamlined delivery of antiretroviral therapy (ART) regardless of CD4 cell count, following community-wide HIV-testing.
Trial: 27604186
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose sunitinib (20 μM for 6-9 h in vitro; once-weekly in vivo)
Trial: 27604186
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily sunitinib (50 mg daily, four weeks on, two weeks off)
Trial: 27604773
Drug: Insulin index
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin index and glycated hemoglobin values
Trial: 27604981
Drug: Hydroxycarbamide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxycarbamide treatment
Trial: 27605156
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and thalidomide therapy
Trial: 27607476
Drug: Long-acting opioids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting opioids (morphine and/or hydromorphone)
Trial: 27611192
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol enriched margarine (3 g/d plant stanols)
Trial: 27611192
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol enriched margarine (3 g/d plant sterols)
Trial: 27612924
Drug: Per-oral endoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per-oral endoscopic tunneling for restoration of the esophagus (POETRE)
Trial: 27612987
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan followed by autologous hematopoietic stem cell transplantation
Trial: 27612987
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy (bortezomib-based in combination with dexamethasone and either thalidomide, cyclophosphamide or lenalidomide) for 4-6 cycles
Trial: 27612987
Drug: Peripheral blood
RxNorm normalized name: Peripheral blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral blood stem cells collected after high-dose cyclophosphamide plus G-CSF or G-CSF alone
Trial: 27612987
Drug: Melphalan at
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan at 140 mg/m² as conditioning regimen
Trial: 27613072
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV) lot released between August 1 and September 15, 2013
Trial: 27613072
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV) lot shipped earlier or later than August 1 to September 15, 2013
Trial: 27613072
Drug: LAIV (trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAIV (trivalent or quadrivalent formulations)
Trial: 27613189
Drug: L-DEP regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DEP regimen (PEG-aspargase and modified DEP regimen)
Trial: 27614912
Drug: [(14)C]prucalopride succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(14)C]prucalopride succinate 2 mg (~200 nCi)
Trial: 27616553
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg once daily; 28-day cycle)
Trial: 27617496
Drug: Interferon-based therapy
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-based therapy
Trial: 27618501
Drug: Once-daily degludec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily degludec
Trial: 27618681
Drug: Objective criteria
RxNorm normalized name: .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SILICON DIOXIDE 4 g in 100 g DENTAL PASTE, DENTIFRICE [the naked object DeBlack PackToothpaste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objective criteria for identifying patients with OHCA with no chance of survival (not witnessed by emergency medical services, nonshockable initial cardiac rhythm, no return of spontaneous circulation before a third 1-mg dose of epinephrine)
Trial: 27619225
Drug: Topical travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical travoprost
Trial: 27621400
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity
Trial: 27621833
Drug: Low eosinophil
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low eosinophil counts (<0.05 compared with 0.15-0.25×10(9)/L)
Trial: 27621833
Drug: Low lymphocyte
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lymphocyte counts (<1.45 vs 1.85-2.15×10(9)/L)
Trial: 27622077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MEDI9447 and anti-PD-1 antibodies
Trial: 27623532
Drug: Task-oriented training
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented training with interactive computer games and objects of daily life
Trial: 27624549
Drug: Decitabine at
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine at 20 mg/m²
Trial: 27624571
Drug: Healthcare-associated infections,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthcare-associated infections, obstructive urinary tract disease, previous surgical history, and use of a cephalosporin antibiotic within 3 months
Trial: 27624579
Drug: Hyperglycemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemic clamp (225 and 400 mg/dl) followed by IV arginine bolus
Trial: 27625358
Drug: HLA allele-matched
RxNorm normalized name: Human Factor XIII (A2) homodimer (allele F13A*1B), recombinant DNA origin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA allele-matched unrelated donor transplant with conditioning regimen including alemtuzumab, fludarabine, and melphalan; GVHD prophylaxis with calcineurin inhibitor, short-course methotrexate, and methylprednisolone.
Trial: 27627050
Drug: Nintedanib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (150 mg for mild impairment, 100 mg for moderate impairment, escalating to 200 mg)
Trial: 27630572
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of five or more medicinal molecules
Trial: 27632289
Drug: HER2-targeted therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HER2-targeted therapy (trastuzumab/pertuzumab)
Trial: 27632680
Drug: Chimeric antigen
RxNorm normalized name: Chimeric antigen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric antigen receptor-modified T cell therapy
Trial: 27632680
Drug: Tocilizumab (interleukin-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (interleukin-6 receptor antibody)
Trial: 27633122
Drug: Sandoz biosimilar
RxNorm normalized name: CLOZAPINE (SANDOZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandoz biosimilar filgrastim, administered twice daily
Trial: 27634203
Drug: Momelotinib 200
RxNorm normalized name: momelotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib 200 mg twice daily
Trial: 27634566
Drug: Pazopanib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib at 800 mg oral daily until disease progression
Trial: 27635072
Drug: Extensive cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensive cardiac workup including ECG, signal averaged ECG, exercise testing, cardiac imaging, Holter-monitoring, and selective provocative drug testing with epinephrine or procainamide
Trial: 27635623
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) delivered in 5 fractions to a dose of 25 to 40 Gy
Trial: 27636400
Drug: FLARE-RA self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLARE-RA self-administered questionnaire
Trial: 27637014
Drug: Anti-mullerian hormone
RxNorm normalized name: Anti-Mullerian hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-mullerian hormone (AMH)
Trial: 27637428
Drug: Romidepsin at
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin at 14 mg/m²
Trial: 27637985
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg orally once daily until progressive disease or unacceptable toxicity
Trial: 27642132
Drug: MenACWY-D (0.5-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-D (0.5-mL booster dose)
Trial: 27642534
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (a combination of aerobic, resistance, and flexibility exercises, average of 2.5 hours a week)
Trial: 27642538
Drug: Metreleptin (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.02 mg/kg BID at Week 1, 0.04 mg/kg BID at Week 2, maximum 0.08 mg/kg BID thereafter)
Trial: 27643485
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg, two infusions
Trial: 27644734
Drug: Anti-tissue transglutaminase
RxNorm normalized name: Anti-tissue transglutaminase IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tissue transglutaminase (anti-tTG) IgA antibodies
Trial: 27644734
Drug: Anti-deamidated gliadin
RxNorm normalized name: Anti-deamidated gliadin peptide IgA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-deamidated gliadin peptide (anti-DGP) IgA antibodies
Trial: 27646946
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously once every 3 weeks
Trial: 27647168
Drug: NOACs (Novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs (Novel Oral Anticoagulants)
Trial: 27647168
Drug: VKA±AP (Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA±AP (Vitamin K Antagonists plus Antiplatelet) or AP (Antiplatelet) alone
Trial: 27647864
Drug: Lenalidomide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (25 mg, days 1-21/28 days) + continuous cyclophosphamide (50 mg/d) + prednisone (20 mg/d)
Trial: 27648290
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral nutritional supplement (ONS)
Trial: 27648294
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m² on day 1 and capecitabine 900 mg/m² two times per day from day 1 to day 14 every 3 weeks (2 cycles)
Trial: 27649927
Drug: Perifosine 50-75
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine 50-75 mg
Trial: 27650822
Drug: Early β
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early β blockers (≤48 hours of admission)
Trial: 27650822
Drug: β blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β blockers at discharge
Trial: 27650822
Drug: Persistence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistence of β blockers at one year
Trial: 27651909
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) containing fluticasone propionate
Trial: 27653085
Drug: MedGem (MG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedGem (MG) vs VMax
Trial: 27653529
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b therapy
Trial: 27653565
Drug: KAF156 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAF156 multiple doses (400 mg once daily for 3 days)
Trial: 27653565
Drug: KAF156 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAF156 single dose (800 mg)
Trial: 27653771
Drug: Single challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single challenge dose of monovalent pediatric hepatitis B vaccine (Engerix™-B Kinder; GSK Vaccines)
Trial: 27654603
Drug: Second anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second anti-TNF drug
Trial: 27654882
Drug: Niacin 500
RxNorm normalized name: niacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 500 mg q1h for 4 doses
Trial: 27654882
Drug: Niacin 500
RxNorm normalized name: niacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 500 mg q2h for 3 doses
Trial: 27654882
Drug: Niacin 250
RxNorm normalized name: niacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 250 mg q2h for 3 doses
Trial: 27654985
Drug: Tenapanor hydrochloride
RxNorm normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenapanor hydrochloride (15 mg twice daily) with sevelamer carbonate (800 mg 3 times daily)
Trial: 27654985
Drug: Tenapanor hydrochloride
RxNorm normalized name: Tenapanor hydrochloride
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenapanor hydrochloride (15 mg twice daily) without sevelamer carbonate
Trial: 27656788
Drug: Ketamine (0.5mg/kg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5mg/kg, administered over 100min) during acute-phase treatment (up to 6 thrice-weekly infusions)
Trial: 27656788
Drug: Continuation-phase treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation-phase treatment with 4 weekly ketamine infusions
Trial: 27656788
Drug: Post-continuation phase
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-continuation phase follow-up (4 weeks, no further ketamine infusions)
Trial: 27656788
Drug: Acute-phase and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute-phase and continuation-phase treatment
Trial: 27658471
Drug: Fecal Microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal Microbiota Transplant (FMT) via duodenal route (44.4%), colonic (41.1%), capsule (9.8%), gastric (3.0%)
Trial: 27658581
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/kg
Trial: 27658740
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg daily for 12 weeks
Trial: 27658863
Drug: Vacc-4x (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacc-4x (12 mg/mL) and rhuGM-CSF (0.6 mg/mL) administered intradermally over 12 weeks followed by romidepsin (5 mg/m2) intravenously once a week for 3 weeks.
Trial: 27658863
Drug: Romidepsin treatment
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin treatment (5 mg/m2) administered intravenously once a week for 3 weeks.
Trial: 27658863
Drug: Vacc-4x and
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacc-4x and rhuGM-CSF followed by romidepsin treatment.
Trial: 27658864
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg long-acting rilpivirine
Trial: 27658864
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg long-acting rilpivirine
Trial: 27658870
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) taken as one tablet per day for a median of 72 weeks
Trial: 27658980
Drug: Acute leukoencephalopathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute leukoencephalopathy during chemotherapy treatment
Trial: 27659464
Drug: First NGAL
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First NGAL <150 ng/ml
Trial: 27660663
Drug: Twice-daily insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily insulin lispro low mixture (LM25)
Trial: 27660663
Drug: Once-daily basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL)
Trial: 27664062
Drug: Gla-300 (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gla-300 (insulin glargine 300 U/mL)
Trial: 27664804
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of glycine and kynurenine alone or in combination